MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
์ข
๋ชฉ ์ฝ๋ MIRA
ํ์ฌ ์ด๋ฆMIRA Pharmaceuticals Inc
์์ฅ์ผAug 03, 2023
CEOAminov (Erez)
์ง์ ์- -
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃAug 03
์ฃผ์1200 Brickell Avenue
๋์MIAMI
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ33131
์ ํ18133695150
์น์ฌ์ดํธhttps://mirapharmaceuticals.com/
์ข
๋ชฉ ์ฝ๋ MIRA
์์ฅ์ผAug 03, 2023
CEOAminov (Erez)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์